Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs Synopsys, Inc. (SNPS) Price & Performance

Citius Pharmaceuticals IncTrade
Synopsys, Inc.Trade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs Synopsys, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while Synopsys, Inc. trades at $410.38 (market cap $78.68B). The key difference: Synopsys, Inc. is far larger — about 3932× Citius Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.

CTXRSNPS
Market Cap
$20.01M$78.68B
Sector
HealthTechnology
52-Week High
$1.82$625.80
52-Week Low
$0.48$372.33
Enterprise Value
$16.23M$87.04B

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About Synopsys, Inc.

Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.

Read more on SNPS